Data On 8 Novel Anticancer Compounds Unveiled By Taiho Pharmaceutical

[News]

Taiho Pharmaceutical Co., Ltd. (HQ: Tokyo, President: Masayuki Kobayashi), the developer of the first orally available fluorouracil (FU) Chemotherapeutic treatment (TS-1/S-1), is presenting early stage data for eight novel oncology compounds, including potential first-in-class therapies...

More... (http://www.medicalnewstoday.com/releases/252500.php)